While the coronavirus has impacted millions of Americans across the United States, it has hit the elderly population particularly hard. In fact, more than 40 percent of coronavirus deaths in the U.S. have been linked to long-term care facilities, according to a New York Times survey. In an effort to bring those numbers down, pharmaceutical company Eli Lilly, in partnership with the National Institutes of Health (NIH), has just launched a late-stage antibody treatment trial focusing on residents and staff at nursing homes.
"COVID-19 has had a devastating impact on nursing home residents," Lilly's chief scientific officer Daniel Skovronsky said in a statement. "We're working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals."
The trial is expected to enroll up to 2,400 participants who live or work at a facility and have recently been diagnosed with the disease. The trial will evaluate the safety and success of using LY-CoV555, a potent, neutralizing antibody that works against the spike protein of the novel coronavirus. The trial will look at whether a single dose of the antibody treatment reduces the rate of infection over four weeks as well as symptoms over eight weeks.
"The importance of these kinds of therapies for people like the elderly or immunocompromised is that they can provide the hope and the safety net that these people really need right now," said Andrew Adams, vice president of new therapeutic modalities & COVID-19 research at Eli Lilly, who is overseeing the trial. "I think people in those populations are really desperate and looking for something to help with the coronavirus."
Eli Lilly is taking its trial on the road with customized mobile research units that can travel directly to areas that are experiencing outbreaks.
"This is an interesting solution, to bring the medicine to these vulnerable patients," said Adams. "This lets us be flexible and move these trials around the country, tracking these trials as we come across them."
Adams said he is hoping Eli Lilly will have results on the efficacy of these antibodies in the fourth quarter of this year. Even if successful, though, he says research for a vaccine needs to continue.
"These have to be thought of as more of a bridge, where a vaccine provides long-term protection in terms of years of immunity, where we will provide hopefully in the range of months with these types of treatments. We hope this to be a short-term bridge to the long-term effective vaccination," he said.
With the emergence of the omicron variant, the U.S. is considering tightening international travel guidelines. The CDC said it might reduce the window for foreign travelers to submit a negative COVID-19 test from three days prior to one day before allowing entry.
Jill and Carlo cover the latest on Omicron, another school shooting in America and more. Plus, bidding farewell to 'transitory' inflation, and the controversy surrounding 'Lovely Bones' author Alice Sebold.
Sarav Arunachalam, air pollution scientist at the University of North Carolina at Chapel Hill, joins Cheddar Climate, where he discusses what he needs to happen when it comes to EV production on a global level to help reduce the effects of climate change.
The United Nations Secretary-General said this year that his agency's warning about climate change was a 'code red for humanity.' So how will political pledges to lower emissions, increase green energy, and ramp up electric vehicle infrastructure play out, and can we reverse some climate damage next year? Vijay Vaitheeswaran, Global energy & climate innovation editor for The Economist, and host of 'To a Lesser Degree,' The Economist’s podcast on climate change, joins Cheddar Climate to discuss what we can look ahead to in 2022, including global policy shifts and investments from the private and public sectors, holding global leaders accountable, and more.
In recent years, extreme weather events like flooding and wildfires have become more frequent, and more severe - and scientists say global warming is to blame. Climate crises could leave people in need of help, and that's where Global Rescue steps in. The crisis response firm employs former Navy Seals and Army Rangers to rescue travelers from climate-related emergencies. Global Rescue CEO Dan Richards joins Cheddar Climate to discuss.
Jennifer Lotito, president and COO at the non-profit (RED), joined Cheddar to discuss the CODE (RED) campaign as the organization looks to expand its mission to support both AIDS and COVID-19 relief. She explained that people can get involved in the campaign for Giving Tuesday and ahead of World AIDS Day by shopping (RED) branded products and even using credit card rewards points to add their own support. Lotito also pointed out that COVID-19 has also impacted HIV testing as people avoid clinics out of fear of the other pandemic.
NASA indefinitely delayed a spacewalk to repair an ISS antenna, citing concerns about space debris. It was unclear if the warning from the space agency to astronauts aboard the ISS was related to the recent destruction of a non-functioning Russian satellite.
